3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
20
Fluorouracil
20
Leucovorin
19
Bevacizumab
16
Cetuximab
13
Irinotecan
12
Capecitabine
8
regorafenib
5
Radiotherapy
5
Nivolumab
5
Drug Therapy
5
aflibercept
4
Radiosurgery
4
Neoadjuvant Therapy
4
Magnetic Resonance Spectroscopy
4
Chemotherapy, Adjuvant
4
Biopsy
4
pembrolizumab
3
durvalumab
3
atezolizumab
3
Specimen Handling
3
Folfox protocol
3
Cyclophosphamide
3
trifluridine tipiracil drug combination
2
tremelimumab
2
tislelizumab
2
poly(I).poly(c12,U)
2
futuximab
2
fludarabine
2
avelumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Colorectal Neoplasms
×
brigimadlin
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn